Description: Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in phase 1/2a clinical trial to treat major depressive disorder (MDD), as well as in preclinical trials for alcohol use disorder; CYB004, a deuterated dimethyltryptamine (DMT), which completed phase 2 clinical trial for treating generalized anxiety disorders; SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 completed phase 1, 1b, and 1/2a for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation, as well as has a research pipeline of investigational psychedelic-based compounds. The company has research and collaboration agreement with TMS Neurohealth Centers Inc. for development of psychedelic compound-based therapeutics; Kernel for use of Kernel flow technology to measure neural activity; and Greenbook TMS to establish mental health centers. The company is headquartered in Toronto, Canada.
Home Page: www.cybin.com
100 King Street West
Toronto,
ON
M5X 1C9
Canada
Phone:
Officers
| Name | Title |
|---|---|
| Mr. Eric So L.L.B. | Co-Founder, President & Executive Chairman |
| Mr. Douglas L. Drysdale | Chief Executive Officer |
| Mr. Paul Glavine | Co-Founder, Chief Growth Officer & Director |
| Mr. Greg Cavers | Chief Financial Officer |
| Mr. Aaron Bartlone | Chief Operating Officer |
| Mr. George Tziras | Chief Business Officer & Director |
| Mr. John Kanakis | Co-Founder |
| Dr. Alex L. Nivorozhkin Ph.D. | Chief Scientific Officer |
| Ms. Lori Challenger | Chief Compliance, Ethics & Administrative Officer |
| Mr. Gabriel Fahel | Chief Legal Officer & Corporate Secretary |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.2114 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | March |
| Full Time Employees: | 50 |